• OPEN AN ACCOUNT
Indian Indices
Sensex
74,294.96 -19.63
( -0.03%)
Global Indices
Nasdaq
51,699.28 -99.76
(-0.19%)
Dow Jones
7,668.45 9.69
(0.13%)
Hang Seng
65,040.24 903.99
(1.41%)
Nikkei 225
10,654.81 -161.33
(-1.49%)
Forex
USD-INR
95.87 0.21
(0.22%)
EUR-INR
110.00 -0.22
(-0.20%)
GBP-INR
128.18 -0.44
(-0.35%)
JPY-INR
0.61 0.00
(-0.09%)

EQUITY - MARKET SCREENER

Tahmar Enterprises Ltd
Industry :  Trading
BSE Code
ISIN Demat
Book Value()
516032
INE385D01029
4.6208333
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
0
81.79
EPS(TTM)
Face Value()
Div & Yield %
0
1
0
 

Indoco Remedies soars after Goa plant clears UK MHRA cGMP inspection
Sep 10,2026
The inspection of the facility, which manufactures solid oral dosage forms, was conducted from 7 September 2026 to 9 September 2026. The UK MHRA's current Good Manufacturing Practices (cGMP) inspection concluded with no critical or major observations, indicating compliance with the regulator's applicable manufacturing standards.

Indoco Remedies is a fully integrated, research-oriented pharmaceutical company with a strong global presence. It develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. Top Indoco brands include Cyclopam, Febrex Plus, ATM, Rexidin M, Karvol Plus, Oxipod, Cital, Sensodent-K, Cital-Uti, Dropizin, Homide, Dentogel, Oxipod CV, Turbocort, Febrex, Cloben G, Tuspel LS, Noxa, MCBM 69, etc.

The company reported a consolidated net profit of Rs 64.99 crore in Q1 FY27 as against a net loss of Rs 35.79 crore in Q1 FY26. Revenue from operations rose 8.43% year on year to Rs 466.22 crore in the first quarter of FY27 from Rs 430.86 crore in the corresponding quarter last year.